中文

Viking Therapeutics (VKTX)

Biotech

Close on Oct 28, 2026 (from our latest article): $25.36

Market value
$3.0Bat the Oct 28 close
Cash used, 12 months
$463M12 months to Sep 30, 2026 (10-Q)
Net cash
$709Mat Sep 30, 2026
Worst fall since listing
−90.4%May 6, 2015 to Aug 2, 2017; back to that high in May 2018

About the company

Latest

  • Quarterly
    Viking Therapeutics Q3 2026: trials on track, spending up 44% and nearly $1 billion in cash

The Long View

Viking began as a licensee of Ligand drug programmes, but since 2023 its story has been VK2735, which it discovered itself.

▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash

Updated Oct 29, 2026

Read the Long View →

Our View Opinion

Viking is a single-asset bet on VK2735, a weekly GIP/GLP-1 injection (the same drug class as Lilly's Zepbound) that also comes as a daily pill.

Median value, end-2030
$48P10–P90 $3.5–$130
Chance of beating the hurdle
62%
Implied end-2030 multiple
7.1× 2031 salesP25–P75 4.5–11.5× · today no sales yet

Biggest risk: The worst realistic case is commercial, not clinical: VANQUISH succeeds, but VK2735 launches in 2029 into a market where retatrutide sets the efficacy bar and Lilly and Novo set prices near $250 a month.

Oct 29, 2026 · our analysis, not investment advice

Read Our View →

More of our coverage that names Viking Therapeutics

Long-term fundamentals

Annual results for Viking Therapeutics, FY2014–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Each year's figures are in the table below. $0$0.0M$0.0M$0.0M$0.0M ’15 ’17 ’19 ’21 ’23 ’25

Margins

Margins are not charted: fewer than two years with revenue and operating income.

Diluted share count

The diluted share count rose 46% from FY2021 to FY2025, to 113M. Each year's figures are in the table below. 70M80M90M100M110M120M ’21’22’23’24’25

The diluted share count rose 46% from FY2021 to FY2025, to 113M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$0——−$360M−$279M——
FY2024$0——−$110M−$88M——
FY2023$0——−$86M−$73M——
FY2022$0——−$69M−$48M——
FY2021$0——−$55M−$48M——
FY2020$0——−$39M−$22M——
FY2019$0——−$26M−$25M——
FY2018$0——−$22M−$19M——
FY2017$0——−$21M−$15M——
FY2016$0——−$15M−$11M——
FY2015$0——−$23M−$9M——
FY2014$0——−$22M−$2M——

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025113M$706M—$41M——
FY2024109M$903M—$30M——
FY202394M$362M—$17M——
FY202277M$155M—$9M—$7M
FY202177M$202M—$6M——
FY2020—$248M—$6M——
FY2019—$276M—$4M——
FY2018—$302M—$3M——
FY2017—$21M—$1M——
FY2016—$3M—$2M—$0.0M
FY2015—$0.8M$2M$3M—$0.0M
FY2014—$0.8M$2M$0.0M—$0.0M

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearVKTXS&P 500
2019+4.8%+31.5%
2020−29.8%+18.4%
2021−18.3%+28.7%
2022+104.4%−18.1%
2023+98.0%+26.3%
2024+116.2%+25.0%
2025−12.6%+17.9%
2026 to date−26.6%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Viking Therapeutics

What does Viking Therapeutics do?
Viking is a clinical-stage drug developer with no products on sale and no revenue, so it funds its spending with money it raises. Its lead drug, VK2735, which it owns outright, activates the GLP-1 and GIP gut-hormone receptors, the same pair targeted by Eli Lilly's tirzepatide. More in the Long View →
What forms of VK2735 is Viking developing?
Viking is developing VK2735 as a weekly injection and a daily tablet for obesity. More in the Long View →
How does Viking pay for its research?
Viking funds research with money raised from investors, including share sales and convertible debt, because it has no product revenue. More in the Long View →
What else is in Viking's pipeline?
VK3019, an amylin-type obesity drug in Phase 1, and older programmes licensed from Ligand Pharmaceuticals: VK2809 and VK0214, both subject to a licence dispute, and VK5211, which Viking intends to partner or license out. More in the Long View →
Which contracts matter most to Viking?
One supplier, CordenPharma, makes VK2735 and receives $150M of prepayments. Ligand could be owed up to about $1.54B in milestones on licensed programmes and is in a court dispute with Viking, and $258.75M of convertible notes are due in 2032. More in the Long View →
What's coming up for Viking's pipeline in the next 12 months?
Viking expects its VANQUISH-1 and VANQUISH-2 Phase 3 trials of the VK2735 injection to complete in 2027, and results from Part 2 of its VK2735 maintenance study in 2027. As of Oct 28, 2026 More in the Long View →

Disclosure: one or more of our editors own shares of Viking Therapeutics (VKTX) as a long-term investment.